Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.46 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.46 |
| ▸ | CHRNA5 | P30532 | 1/20 | 0.46 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
| ▸ | TGM2 | P21980 | 1/20 | 0.44 |
| ▸ | VCP | P55072 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL38181 | 0.94 | — | — | |
| SCHEMBL29463713 | 0.94 | — | — | |
| SCHEMBL28168759 | 0.92 | LMNA (0.56) | LMNAHTTALDH1A1MEN1KMT2A | |
| Methylamine SCHEMBL10683872 | 0.92 | LMNA (0.56) | LMNAHTTALDH1A1MEN1KMT2A | |
| SCHEMBL27759469 | 0.92 | LMNA (0.59) | LMNAHTTALDH1A1MEN1KMT2A | |
| Methane SCHEMBL27809994 | 0.92 | LMNA (0.59) | LMNAHTTALDH1A1MEN1KMT2A | |
| Formaldehyde SCHEMBL27348283 | 0.90 | LMNA (0.57) | LMNAHTTALDH1A1MEN1KMT2A | |
| Formaldehyde SCHEMBL27970039 | 0.90 | LMNA (0.57) | LMNAHTTALDH1A1MEN1KMT2A | |
| Ethylene SCHEMBL27728655 | 0.90 | LMNA (0.57) | LMNAHTTALDH1A1MEN1KMT2A | |
| Pyridine SCHEMBL8405328 | 0.88 | LMNA (0.56) | LMNAHTTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-05-23 | — | — | US | disclosed |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2024-04-25 | — | — | US | disclosed |
| EP-4025253-B1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR SA (ES) | 2024-03-20 | — | — | EP | disclosed |
| EP-3615544-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-4101855-B9 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2024-01-03 | — | — | EP | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| EP-4101855-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-02 | — | — | EP | disclosed |
| US-11713325-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2023-08-01 | — | — | US | disclosed |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | PHARMA MAR, S.A. (ES) | 2023-07-13 | — | — | US | disclosed |
| WO-2023067132-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2023-04-27 | — | — | WO | disclosed |
| EP-2792683-A1 | Compounds potentiating the activity of antifungal drugs | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2014-10-22 | — | — | EP | disclosed |
| US-8748388-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-06-10 | — | — | US | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
| EP-2231695-A1 | ANTITUMORAL COMPOUNDS | Pharma Mar S.A. (ES) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009077401-A1 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2009-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | LMNA 930/4885HTT 950/4885ALDH1A1 3310/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | LMNA 3075/4885HTT 2710/4885ALDH1A1 319/4885 |
| US-20240131180-A1 | DRUG ANTIBODY CONJUGATES | STT3B, STT3A, TTL | LMNA 1254/4885HTT 827/4885ALDH1A1 785/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | LMNA 3075/4885HTT 2710/4885ALDH1A1 319/4885 |
| US-20240166666-A1 | ANTITUMORAL COMPOUNDS | TP53, TOP1, MCL1 | LMNA 1898/4885HTT 3353/4885ALDH1A1 144/4885 |
| US-11713325-B2 | Antitumoral compounds | TP53, TOP1, MCL1 | LMNA 1898/4885HTT 3353/4885ALDH1A1 144/4885 |
| US-20230218774-A1 | DRUG ANTIBODY CONJUGATES | B3GAT3, MGAT3, SDAD1 | LMNA 3861/4885HTT 3417/4885ALDH1A1 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.